Introduction Digestive neuroendocrine carcinomas (NEC) are rare but highly aggressive malignancies with poor prognosis and limited therapeutic options. Standard first-line therapy consists of platinum plus etoposide, extrapolated from small-cell lung cancer, but outcomes remain suboptimal, particularly in colorectal NEC and tumours with intermediate Ki67 (20%–55%).
Introduction
Digestive neuroendocrine carcinomas (NEC) are rare but highly aggressive malignancies with poor prognosis and limited therapeutic options. Standard first-line therapy consists of platinum plus etoposide, extrapolated from small-cell lung cancer, but outcomes remain suboptimal, particularly in colorectal NEC and tumours with intermediate Ki67 (20%–55%). In the absence of established second-line therapies, regimens effective in adenocarcinomas, such as FOLFIRINOX, are increasingly being explored in this setting.
Problem Statement
There is a significant unmet need for effective second-line or later-line treatment in digestive NEC. Current evidence is scarce, and treatment decisions are largely empirical, especially for patients progressing after platinum-based therapy or those with biologically distinct subgroups such as lower Ki67 tumours.
Summary
This Scandinavian multicenter retrospective study evaluated FOLFIRINOX in 50 patients with digestive NEC. The regimen demonstrated promising activity with an overall response rate of 44% and a disease control rate of 72%, alongside a median progression-free survival of 5.6 months. Notably, efficacy was maintained in challenging subgroups, including colorectal primaries, Ki67 <55%, and patients previously treated with platinum–etoposide. These findings suggest that FOLFIRINOX may represent a valuable therapeutic option beyond first-line treatment in NEC. Although limited by retrospective design, this study provides important real-world evidence supporting broader consideration of FOLFIRINOX in aggressive neuroendocrine malignancies.
Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma...
Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term...
Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond...
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.